3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
23
Paclitaxel
14
pembrolizumab
8
liposomal doxorubicin
7
Bevacizumab
5
Specimen Handling
4
olaparib
3
niraparib
3
epacadostat
3
Topotecan
3
Taxes
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Cyclophosphamide
3
Biopsy
3
sarilumab
2
rucaparib
2
poly ICLC
2
durvalumab
2
cemiplimab
2
STA 9090
2
Injections
2
Immunoglobulin G
2
Drug Therapy
2
Docetaxel
2
Disulfides
2
Cisplatin
2
veliparib
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Fallopian Tube Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts